Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options

• MTOR pathway genes are often mutated in ovarian clear cell carcinomas (OCCC). • 11.2% of OCCC have targetable alterations only in the mTOR pathway. • MTOR pathway mutations in OCCC can underlie robust, lasting responses to everolimus.

Detalles Bibliográficos
Autores principales: Elvin, Julia A., Chura, Justin, Gay, Laurie M., Markman, Maurie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357688/
https://www.ncbi.nlm.nih.gov/pubmed/28349114
http://dx.doi.org/10.1016/j.gore.2017.02.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357688/
https://www.ncbi.nlm.nih.gov/pubmed/28349114
http://dx.doi.org/10.1016/j.gore.2017.02.007

Ejemplares similares